Cargando…
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form of a glycolipid antigen known as GD2. It has restricted expression in normal tissue, such as peripheral afferent nerves. Monoclonal antibodies targeting GD2 have been applied clinically to high-risk n...
Autores principales: | Chan, Godfrey Chi-Fung, Chan, Carol Matias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945428/ https://www.ncbi.nlm.nih.gov/pubmed/35327550 http://dx.doi.org/10.3390/biom12030358 |
Ejemplares similares
-
Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021) -
Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022) -
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021) -
Correction to: Multidisciplinary Clinical Care in the Management of Patients Receiving Anti‑GD2 Immunotherapy for High‑Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2023) -
Mesenchymal stem cells accelerated growth and metastasis of neuroblastoma and preferentially homed towards both primary and metastatic loci in orthotopic neuroblastoma model
por: Yu, Jiao-Le, et al.
Publicado: (2021)